Anebulo Pharmaceuticals News

Anebulo Pharmaceuticals: Strong Buy Rating Amid Promising Clinical Advances and Rapid FDA Track

TipRanksFeb 15 14:25 ET

Rising Cannabis Hospitalizations and Leadership Transition Boost Anebulo Pharmaceuticals' Outlook: A Buy Rating Analysis

TipRanksOct 26, 2023 13:26 ET

Benchmark Reiterates Speculative Buy on Anebulo Pharmaceuticals, Maintains $8 Price Target

BenzingaOct 3, 2023 11:52 ET

Anebulo Pharmaceuticals Analyst Ratings

BenzingaOct 3, 2023 11:50 ET

HC Wainwright & Co. Reiterates Buy on Anebulo Pharmaceuticals, Maintains $6 Price Target

BenzingaSep 25, 2023 06:10 ET

Anebulo Pharmaceuticals Analyst Ratings

BenzingaSep 25, 2023 06:09 ET

Anebulo Pharmaceuticals Analyst Ratings

BenzingaSep 21, 2023 11:48 ET

HC Wainwright & Co. Initiates Coverage On Anebulo Pharmaceuticals With Buy Rating, Announces Price Target of $6

BenzingaSep 18, 2023 06:33 ET

Anebulo Pharmaceuticals Analyst Ratings

BenzingaSep 18, 2023 06:32 ET

Anebulo Pharmaceuticals (ANEB) Has a New Rating From H.C. Wainwright

TipRanksSep 18, 2023 06:25 ET

Benchmark Reiterates Speculative Buy on Anebulo Pharmaceuticals, Maintains $8 Price Target

BenzingaMay 18, 2023 09:39 ET

Anebulo Pharmaceuticals Analyst Ratings

Benzinga Analyst RatingsFeb 14, 2023 08:28 ET

Ladenburg Thalmann Initiates Anebulo Pharmaceuticals at Buy with $6 Price Target

MT NewswiresJul 27, 2022 09:00 ET

Anebulo Pharmaceuticals Initiated at Buy by Ladenburg Thalmann

Dow JonesJul 27, 2022 08:32 ET

Anebulo Pharmaceuticals Price Target Announced at $6.00/Share by Ladenburg Thalmann

Dow JonesJul 27, 2022 08:32 ET

Anebulo Pharmaceuticals analyst ratings

Benzinga Analyst RatingsJul 27, 2022 08:24 ET

Ladenburg Thalmann Initiates Coverage On Anebulo Pharmaceuticals with Buy Rating, Announces Price Target of $6

Benzinga Real-time NewsJul 27, 2022 08:24 ET